BCMA Targeted Therapies Archives -

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU

CHMP backs J&J’s myeloma CAR-T therapy Carvykti

https://pharmaphorum.com/news/chmp-backs-jjs-myeloma-car-t-therapy-carvykti/

Johnson & Johnson’s much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and

J&J goes after another FDA approval for a cancer bispecific

https://pharmaphorum.com/news/jj-guns-for-another-fda-approval-for-a-cancer-bispecific/

After dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by

AbbVie jumps on the BCMA train, opting into TeneoOne buy

https://pharmaphorum.com/news/abbvie-jumps-on-the-bcma-train-opting-into-teneoone-buy/

Johnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel),

FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-cel

https://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe,

Janssen files its first CAR-T therapy cilta-cel in Europe

https://pharmaphorum.com/news/janssen-files-its-first-car-t-therapy-cilta-cel-in-europe/

Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies

BCMA Targeted Therapies Summit

https://pharmaphorum.com/events/bcma-targeted-therapies-summit/

BCMA Targeted Therapies